CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...
Phase 1, Phase 2
Dallas, Texas, United States and 55 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Dallas, Texas, United States and 7 other locations
The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...
Phase 2, Phase 3
Fort Worth, Texas, United States and 7 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Dallas, Texas, United States and 108 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Dallas, Texas, United States and 23 other locations
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...
Phase 1, Phase 2
Fort Worth, Texas, United States and 11 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Dallas, Texas, United States and 110 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Dallas, Texas, United States and 22 other locations
of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...
Phase 1, Phase 2
Dallas, Texas, United States and 48 other locations
chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor recept...
Phase 1
Dallas, Texas, United States and 1 other location
Clinical trials
Research sites
Resources
Legal